MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
about
The Mcm2-7 replicative helicase: a promising chemotherapeutic targetmiR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesisMCM Paradox: Abundance of Eukaryotic Replicative Helicases and Genomic Integrity.Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapiesCombining multi-dimensional data to identify key genes and pathways in gastric cancerTargeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLCDownregulation of growth differentiation factor-15 in trichostatin A-induced apoptosis could play a role in progression of gastric cancer.Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells.Expression and Splice Variant Analysis of Human TCF4 Transcription Factor in Esophageal Cancer.Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation.Informed walks: whispering hints to gene hunters inside networks' jungleMCM2-regulated functional networks in lung cancer by multi-dimensional proteomic approach.Effect of trichostatin a on SGC-7901 gastric cancer cells.The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat.The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer
P2860
Q26861045-E798EE27-EFD5-461A-81EC-FADC3B261140Q34023389-37813056-6E27-4D32-8E46-C481F91D211BQ34441575-66AB9BCD-B324-4693-B04F-6B51BAD433C7Q35769403-1B64EE1C-3E01-4800-BD05-8D3FE65CF14DQ36398831-8A581899-7E29-4C64-90A7-9FCE9DEACCD9Q36544248-F180EAB1-CC60-4FE5-AFB4-CE94C7E73A70Q37645002-F850280B-73F2-4100-BCA5-02B393705E03Q38837934-A2BB90A9-7162-453E-A108-B3B433FD5A40Q38844402-425A7AC9-A935-4372-BB0A-4EB4D5574009Q38900424-3255B3C1-F5BC-4D9E-9466-E9C42C3CFBB9Q38911571-5DE031CA-01D2-4144-9261-902F0D82CAD2Q39022633-18EFBDC1-A509-43DA-90AD-EC253ED927C3Q39079713-5526E81B-3F3E-4572-9B69-C83282DE4809Q42375160-24C5E403-AA34-4668-803A-483012DD0269Q42378823-D6CA151B-169E-46A8-8EFC-F4D657664B54Q42873813-640184C9-200C-481C-B202-3C6D2B4614F8Q46280254-783C3451-A683-4388-A3B3-D0C9E342CB60Q48379148-98995F9E-00DB-42A3-A18E-9C7D75F779DEQ52322877-C5D3BC9D-CAEC-46F6-AEAD-80DE73CCA582Q58717634-7FB10914-D87D-4BF4-82DF-BCAE32227B0B
P2860
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@en
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@nl
type
label
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@en
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@nl
prefLabel
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@en
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@nl
P2093
P1433
P1476
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
@en
P2093
P356
10.1016/J.TOXLET.2013.05.643
P577
2013-06-13T00:00:00Z